Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

TerminatedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions
Glioblastoma
Interventions
DEVICE

Optune

"Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme."

Trial Locations (1)

76508

Baylor Scott and White Medical Center, Temple

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER

NCT03403803 - Prognosis and Therapeutic Biomarkers for Glioblastoma Patients | Biotech Hunter | Biotech Hunter